Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 entities : Ocuphire pharma inc. save search
Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances
Published: 2022-05-19 (Crawled : 12:00) - biospace.com/
OCUP | $1.66 -0.6% -0.6% 230K
|
Health Technology
|
| O: -15.14%
H: 13.51%
C: 10.27%
nyxol topline eye trial positive phase 3
Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis
Published: 2022-03-29 (Crawled : 12:00) - biospace.com/
OCUP | $1.66 -0.6% -0.6% 230K
|
Health Technology
|
| O: -12.82%
H: 7.96%
C: -3.91%
nyxol fda trial positive results topline phase 3
Ocuphire Completes Enrollment in MIRA-3 Pivotal Phase 3 Clinical Trial for Nyxol® in RM and Announces Two Upcoming Medical Conference Presentations
Published: 2022-02-08 (Crawled : 19:00) - biospace.com/
OCUP | $1.66 -0.6% -0.6% 230K
|
Health Technology
|
| O: -0.34%
H: 8.47%
C: 8.47%
nyxol trial conference presentation phase 3 enroll
Ocuphire Provides Corporate Update: Announcing Enrollment Completion of Phase 3 Nyxol Trial, Enrollment Initiation of Nyxol Pediatric Trial, and an Investor R&D Day in January
Published: 2022-01-05 (Crawled : 12:30) - globenewswire.com
OCUP | $1.66 -0.6% -0.6% 230K
|
Health Technology
|
| O: -0.26%
H: 2.49%
C: -3.93%
nyxol trial phase 3 enroll
Ocuphire Announces Enrollment of First Patients in Second Phase 3 Pivotal Trial (MIRA-3) for Nyxol® in Reversal of Mydriasis (RM)
Published: 2021-11-23 (Crawled : 14:30) - biospace.com/
OCUP | $1.66 -0.6% -0.6% 230K
|
Health Technology
|
| O: -0.29%
H: 0.0%
C: 0.0%
nyxol phase 3 trial enroll
Ocuphire Announces MIRA-2 Phase 3 Registration Trial for the Reversal of Mydriasis Meets Primary Endpoint
Published: 2021-03-15 (Crawled : 11:00) - globenewswire.com
OCUP | $1.66 -0.6% -0.6% 230K
|
Health Technology
|
| O: 16.6%
H: 6.04%
C: -9.6%
phase 3 trial
Ocuphire Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis
Published: 2021-01-06 (Crawled : 12:03) - globenewswire.com
OCUP | $1.66 -0.6% -0.6% 230K
|
Health Technology
|
| O: 0.0%
H: 1.32%
C: -4.64%
phase 3 trial enroll
Ocuphire Pharma Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbances
Published: 2021-01-05 (Crawled : 12:03) - globenewswire.com
OCUP | $1.66 -0.6% -0.6% 230K
|
Health Technology
|
| O: 1.57%
H: 7.59%
C: 6.19%
phase 3 pharma
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.